Hansoh Pharmaceutical Group (HKG:3692) said a new indication for the inebilizumab injection to treat immunoglobulin G4-related disease has been included in the Priority Review and Approval Procedure by the National Medical Products Administration of China.
The pharmaceutical company had entered into an agreement with Viela Bio to obtain an exclusive license to develop and commercialize the drug in China's mainland, Hong Kong, and Macao, a Monday Hong Kong bourse filing said.
Viela Bio has since been acquired by Horizon Therapeutics, which was bought by Amgen in 2023.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.